Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Non-Hodgkin 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms, Plasma Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Lymphoid 1Leukemia, Large Granular Lymphocytic 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 160Rituximab 82Peripheral Blood Stem Cell Transplantation 78fludarabine phosphate 75Etoposide 69Filgrastim 67Methotrexate 59Cytarabine 58Vincristine 50Mycophenolic Acid 50Whole-Body Irradiation 48Radiotherapy 43Cyclosporine 43Busulfan 42Tacrolimus 40Melphalan 39Dexamethasone 37Prednisone 36Doxorubicin 36Antilymphocyte Serum 36fludarabine 31blinatumomab 27Methylprednisolone 24Granulocyte Colony-Stimulating Factor 22Carmustine 22Cord Blood Stem Cell Transplantation 21Calcium Dobesilate 18CT-P10 18Inotuzumab Ozogamicin 16sargramostim 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Burkitt Lymphoma × duvelisib × Clear all
NCT02028039 2014-01-06

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡